Apyx Medical Corp DEF 14A, filed Aug 4, 2006: DEF 14A
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION (Rule 14a-101)
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934 (Amendment No.)
Filed
by
the Registrant [X] Filed by a Party other than the Registrant [ ] Check the
appropriate box:
|
[
]
Preliminary Proxy Statement
|
[
]
Confidential, for Use of the
|
|
[X]
Definitive Proxy Statement
|
Commission
Only (as Permitted by Rule
|
|
[
]
Definitive Additional Materials
|
14a-6(e)
(2))
|
|
[
]
Soliciting Material Pursuant to
|
|
|
Rule
14a-11(c) or Rule 14a-12
|
BOVIE
MEDICAL CORPORATION
(Name
of
the Registrant as Specified In Its Charter)
(Name
of
Person(s) Filing Proxy Statement, if other then the Registrant)
Payment
of Filing Fee (Check the appropriate box):
|
[X]
|
No
fee required
|
|
[
]
|
Fee
computed on table below per Exchange Act Rules 14a-6(i) (4) and
0-11.
|
|
1.
|
Title
of each class of securities to which transaction applies:
_____
|
|
2.
|
Aggregate
number of securities to which transaction applies:
_________
|
|
3.
|
Per
unit price or other underlying value of transaction computed pursuant
to
Exchange Act Rule 0-11 (Set forth the amount on which the filing
fee is
calculated and state how it was determined):
____________
|
|
4.
|
Proposed
maximum aggregate value of transaction: ______________
|
|
5.
|
Total
fee paid: _______________________________
|
|
[
]
|
Fee
paid previously with preliminary materials
|
|
[
]
|
Check
box if any part of the fee is offset as provided by Exchange Act
Rule
0-11(a) (2) and identify the filing for which the offsetting fee
was paid
previously. Identify the previous filing by registration statement
number,
or the Form or Schedule and the date of its filing.
|
|
1.
|
Amount
Previously Paid:
|
|
2.
|
Form,
Schedule or Registration Statement No.:
|
|
3.
|
Filing
Party:
|
|
4.
|
Date
Filed:
|
Bovie
Medical Corporation
734
Walt Whitman Road Suite 207
Melville,
NY 11747
August
11, 2006
|
Re:
|
Notice
of Annual Meeting and Proxy
Statement
|
Dear
Stockholder:
On
behalf
of your Board of Directors and Management, you are cordially invited to attend
the Annual Meeting of Common Stockholders to be held on September 14, 2006
at 5
P.M. eastern daylight time at the Holiday Inn, 215 Sunnyside Boulevard,
Plainview, New York 11803.
Information
Concerning Solicitation and Voting
The
Board
of Directors is soliciting proxies for the 2005 Annual Meeting of Stockholders
to be held on September 14, 2006. This Proxy Statement contains information
for
you to consider when deciding how to vote on the matters brought before the
meeting.
Voting
materials, which include the Proxy Statement, Proxy Card and the 2005 Annual
Report, are being mailed to stockholders on or about August 11, 2006. The
Executive facilities of our Company are located at 734 Walt Whitman Road,
Suite
207, Melville, NY 11747, telephone number 631-421-5452.
At
the
meeting, stockholders will be asked to:
|
1.
|
Elect
Bovie’s entire Board of Directors, and
|
|
2.
|
Ratify
the selection of Bovie’s independent auditors for 2006.
|
|
3.
|
Stockholders
may be asked to transact such other business that may properly come before
the meeting.
|
The
close
of business on July 25, 2006 is the record date for determining stockholders
entitled to vote at the Annual Meeting. Consequently, only stockholders whose
names appear on our books as owning our Common Stock at the close of business
on
July 25, 2006 will be entitled to notice of and to vote at the Annual Meeting
and adjournment of postponement thereof.
PLEASE
COMPLETE, SIGN, DATE AND PROMPTLY RETURN THE PROXY IN THE ENCLOSED ENVELOPE,
SO
THAT YOUR SHARES WILL BE REPRESENTED WHETHER OR NOT YOU ATTEND THE ANNUAL
MEETING.
|
By
order of the board of directors
|
|
/s/
Andrew Makrides
|
|
PRESIDENT
AND CHIEF EXECUTIVE OFFICER
|
|
August
11, 2006
|
PROXY
STATEMENT
BOVIE
MEDICAL CORPORATION
|
CONTENTS
|
|
|
Page
|
|
|
ANNUAL
REPORT
|
4
|
|
STOCK
OWNERSHIP
|
4
|
|
MANAGEMENT
|
6
|
|
MEETINGS
OF THE BOARD OF DIRECTORS
|
7
|
|
DIRECTORS'
COMPENSATION
|
7
|
|
EXECUTIVE
COMPENSATION
|
8
|
|
BENEFICIAL
OWNERSHIP OF SECURITIES
|
12
|
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
|
14
|
|
PRINCIPAL
ACCOUNTANT FEES AND SERVICES
|
15
|
|
OTHER
BUSINESS
|
16
|
|
PROPOSAL
ONE: ELECTION OF DIRECTORS
|
17
|
|
PROPOSAL
TWO: RATIFACTION OF SELECTION OF AUDITORS
|
17
|
Information
Concerning Solicitation and Voting
Our
Board
of Directors is soliciting proxies for the 2005 Annual Meeting of Stockholders
to be held on September 14, 2006. This Proxy Statement contains important
information for you to consider when deciding how to vote on the matters
brought
before the meeting.
Voting
materials, which include the Proxy Statement, Proxy Card and the 2005 Annual
Report, are being mailed to stockholders on or about August 11, 2006. The
Executive facilities of our Company are located at 734 Walt Whitman Road,
Suite
207 Melville, NY 11747.
Bovie
will bear the expense of soliciting proxies. We will reimburse banks, brokers
and other custodians, nominees and fiduciaries for reasonable charges and
expenses incurred in forwarding soliciting materials to their
clients.
1
ABOUT
THE ANNUAL MEETING
WHO
IS
SOLICITING YOUR VOTE?
The
Board
of Directors of Bovie Medical Corporation ("Bovie") is soliciting your vote
at
the Annual Meeting of Bovie's common stockholders being held on September
14,
2006.
WHAT
WILL YOU BE VOTING ON?
Election
of Bovie's Board of Directors (see page 19). 2. Ratification of BLOOM & CO.,
LLP as Bovie's auditors for 2006 (see page 20).
HOW
MANY VOTES DO YOU HAVE?
You
will
have one vote for every share of the Company's common stock you owned of
record
on July 25, 2006 (the record date).
HOW
MANY VOTES CAN BE CAST BY ALL COMMON STOCKHOLDERS?
One
vote
for each of the Company's outstanding shares of common stock which were
outstanding on the record date. The common stock will vote as a single class
on
all matters scheduled to be voted on at the Annual Meeting. There is no
cumulative voting.
HOW
MANY VOTES MUST BE PRESENT TO HOLD THE MEETING?
A
majority of the votes that can be cast, or a minimum of 7,324,968 votes must
be
present in person or by proxy in order to hold the meeting.
HOW
DO
YOU VOTE?
|
·
|
You
can vote either in person at the Annual Meeting or by proxy without
attending the Annual Meeting. We urge you to vote by proxy even
if you
plan to attend the Annual Meeting; so that we will know as soon
as
possible that enough votes will be present for us to hold the
meeting.
|
|
·
|
To
vote by proxy, you must fill out the enclosed proxy, date and sign
it, and
return it in the enclosed postage-paid envelope.
|
|
·
|
If
you want to vote in person at the Annual Meeting, and you hold
your Bovie
stock through a securities broker (that is, in street name), you
must
obtain a proxy from your broker and bring that proxy to the
meeting.
|
CAN
YOU CHANGE YOUR VOTE?
Yes.
Just
send in a new proxy with a later date, or send a written notice of revocation
to
the attention of Bovie's Secretary at the address on the cover of this proxy
statement. If you attend the Annual Meeting and want to vote in person, you
can
request that your previously submitted proxy not be used.
WHAT
IF YOU DO NOT VOTE FOR SOME OF THE MATTERS LISTED ON YOUR PROXY?
If
you
return a signed proxy without indicating your vote, your shares will be voted
"FOR" each of the director nominees listed on the proxy, and "FOR" Bloom
&
Co., LLP as auditor.
2
WHAT
IF YOU VOTE "ABSTAIN"?
A
vote to
"abstain" on any matter indicates that your shares will not be voted for
such
matter and will have the effect of a vote against the proposal.
CAN
YOUR SHARES BE VOTED IF YOU DO NOT RETURN YOUR PROXY AND DO NOT ATTEND THE
ANNUAL MEETING?
|
·
|
That
depends upon whether the shares are registered in your name or
your
broker's name ("street name"). If you do not vote your shares held
in
street name, your broker can vote your shares on any of the matters
scheduled to come before the meeting.
|
|
·
|
If
you do not vote your shares held in your broker's name, or "street
name",
and your broker or its representative does not vote them, the votes
will
be broker non votes, which will have no effect on the vote for
any matter
scheduled to be considered at the Annual Meeting.
|
|
·
|
If
you do not attend and vote your shares which are registered in
your name
or if you do not otherwise fill out the proxy card and vote by
proxy, your
shares will not be voted.
|
COULD
OTHER MATTERS BE DECIDED AT THE ANNUAL MEETING?
We
do not
know of any other matters that will be considered at the Annual Meeting.
If a
stockholder proposal that was excluded from this proxy statement is otherwise
properly brought before the meeting, we will vote the proxies against that
proposal. If any other matters arise at the Annual Meeting, the proxies will
be
voted at the discretion of the proxy holders.
WHAT
HAPPENS IF THE MEETING IS POSTPONED OR ADJOURNED?
Your
proxy will still be valid and may be voted at the postponed or adjourned
meeting. You will still be able to change or revoke your proxy until it is
actually voted.
3
ANNUAL
REPORT
The
Company has included herewith a copy of its Annual Report for the fiscal
year
ended December 31, 2005 ("2005 Annual Report"). Additional
copies of the 2005 Annual Report may be obtained by Stockholders without
charge
by writing to Andrew Makrides, President, at the Company's New York offices
at
734 Walt Whitman Road Melville, NY 11747. Any written request shall set forth
a
good faith representation that the person making the request is a beneficial
owner of the securities of Bovie and entitled to vote as of July 25, 2006,
the
record date.
Confidentiality
It
is the
Company's policy that all proxies, ballots and voting materials that identify
the particular vote of a stockholder are kept confidential, except in the
following circumstances:
|
·
|
to
allow the election inspector appointed for our Annual Meeting to
certify
the results of the vote;
|
|
·
|
as
necessary to meet applicable legal requirements, including the pursuit or
defense of a judicial action;
|
|
·
|
where
we conclude in good faith that a bona fide dispute exists as to
the
authenticity of one or more proxies, ballots, or votes, or as to
the
accuracy of the tabulation of such proxies, ballots, or
votes;
|
|
·
|
where
a stockholder expressly requests disclosure or has made a written
comment
on a proxy;
|
|
·
|
Where
contacting stockholders by us is necessary to obtain a quorum,
the names
of stockholders who have or have not voted (but not how they voted)
may be
disclosed to us by the election inspector appointed for the Annual
Meeting;
|
|
·
|
aggregate
vote totals may be disclosed to us from time to time and publicly
announced at the meeting of stockholders at which they are relevant;
and
in the event of any solicitation of proxies with respect to any
of our
securities by a person other than us of which solicitation we have
actual
notice.
|
STOCK
OWNERSHIP
We
encourage stock ownership by our directors, officers and employees to align
their interests with the interests of stockholders. Management further believes
this policy has played a significant role in the progress of our company
and
will, ultimately, lead to beneficial future returns for its stockholders.
Management also offers incentives and fosters stock ownership by all of its
employees through various measures, such as stock option grants, restricted
stock awards, and participation in developing programs.
4
BOARD
OF DIRECTORS
Director
Selection
Bovie
does not have any standing nominating committee or compensation committee.
All
candidates for the office of director are determined by the Board of Directors.
Given Bovie's present size and organization and the increasing participation
of
the members of the Board in matters relating to expansion of markets for
Bovie's
business, development of new technologies and allocation of resources, attention
has not previously been given to the formation of nominating or compensation
committees. Each member of the Board of Directors participates in the
consideration of director nominees. The Board of Directors consists of six
members, four of which qualify as independent directors, as such terms are
defined under the rules of the American Stock Exchange.
The
Board
of Directors has not adopted any policy, code or charter for its nominating
process, but in keeping with the current legislative environment intends
to
establish, where practicable and necessary, such nominating committee and
charter and compensation committee in the future. Presently, the Board considers
them, especially skills and qualities of a potential director nominee with
experience and expertise in the areas of finance, management and business
as
desirable qualities in a potential director nominee. The Board will
consider nominees provided by a qualified security holder or holders
representing at least 5% of Bovie's outstanding common stock, and that such
shares were owned by the security holder making the nomination for at least
one
year prior to the nomination. See Other Business elsewhere in this proxy
statement.
5
Management
The
following table sets forth certain information as of the record date, regarding
each of the executive officers and directors of the Company. The Company's
Executive Officers and directors are as follows:
|
Name
|
Position
|
Director
Since
|
|
Andrew
Makrides
|
Chairman
of the Board,
|
December,
1982
|
|
President,
CEO, Principal
|
||
|
Accounting
Officer and Director
|
||
|
J.
Robert Saron
|
Director
and President of
|
August,
1994
|
|
Aaron
Medical Industries, Inc.
|
||
|
George
W. Kromer, Jr.
|
Director
|
October,
1995
|
|
Randy
Rossi
|
Director
|
August,
2004
|
|
Michael
Norman
|
Director
|
August,
2004
|
|
Brian
H. Madden
|
Director
|
September,
2003
|
|
Moshe
Citronowicz
|
Executive
Vice-President
|
-------
|
|
Chief
Operating Officer
|
Andrew
Makrides,
age 64,
Chairman of the Board of Directors, President, and Chief Executive Officer,
received a Bachelor of Arts degree in Psychology from Hofstra University
and a
Doctor of Jurisprudence JD Degree from Brooklyn Law School. He is a member
of
the Bar of the State of New York and practiced law from 1968 until joining
Bovie
Medical Corporation as Executive Vice President and director, in 1982. Mr.
Makrides became President of the Company in 1985 and the CEO in December
1998
and has served as such to date.
J.
Robert Saron,
age 53,
Director, holds a Bachelors degree in Social and Behavioral Science from
the
University of South Florida. From 1988 to present Mr. Saron has served as
a
president and director of Aaron Medical Industries, Inc. ("Aaron"), Bovie’s
wholly owned marketing subsidiary. Mr. Saron served as CEO and chairman of
the
Board of the Company from 1994 to December 1998. Mr. Saron is presently the
President of Aaron and a member of the Board of Directors of the
Company.
Randy
Rossi,
age 46,
has over 14 years of experience in medical manufacturing. Most recently,
he was
President of the Patient Care Division, Kendall/TYCO which specialized in
Wound
Care, Urology and Incontinent Care with revenues in excess of $500M.
George
W. Kromer, Jr.,
age
66, filled a vacancy on the Board of Directors and became a director on October
1, 1995. Mr. Kromer has in the past served as a Senior Financial Correspondent
for "Today's Investor" and has been employed as a consultant by a number
of
companies, both private and public. Mr. Kromer as chairman to the audit
committee in addition to his capacity as a director. He received a Master's
Degree in 1976 from Long Island University in Health Administration. He was
engaged as a Senior Hospital Care Investigator for the City of New York Health
& Hospital Corporation from 1966 to 1986. He also holds a Bachelor of
Science Degree from Long Island University's Brooklyn Campus and an Associate
in
Applied Science Degree from New York City Community College, Brooklyn, New
York.
6
Michael
Norman,
CPA age
50, manages a CPA firm specializing in business financial planning as well
as
governmental and financial auditing. Mr. Norman is a member of the Nassau
County
Board of Assessors, Treasurer of the Don Monti Memorial Research Foundation
and
a Glen Cove City Councilman, all located on Long Island, New York. He also
serves as the expert member of Bovie’s audit committee.
Brian
H. Madden,
age 52,
joined the Board of Directors in September 2003. He is an officer and principal
owner of Liberty Title Agency LLC, a non-affiliated, privately owned full
service title insurance agency located in Garden City, N.Y. He also serves
on a
number of non-affiliated professional, charitable and civic organizations
including, among others, the New York State Land Title Association, National
Federation of Independent Businesses, Long Island Children's Museum, SUNY
Old
Westbury Foundation, and Our Lady of Consolation Nursing Home. Mr. Madden
is a
member of our recently formed Audit Committee. He graduated Iona College
with a
BBA Degree in 1976.
MEETINGS
OF THE BOARD OF DIRECTORS
The
Board
of Directors (the "Board") had six Meetings of the Board of Directors in
2005,
each of which was attended by all directors, including telephonic meetings
of
the Board. Our audit committee was established in 2003, and presently consists,
of Brian H. Madden, George W. Kromer, chairman and Michael Norman each of
whom
qualify as independent directors under the rules promulgated by the American
Stock Exchange. The Board of Directors continues to manage Bovie's various
stock
option Plans and the participation activity requirements for each member
of the
Board are increasing as we are aggressively pursuing and implementing new
marketing and other strategies. Due to the limited number of members and
the
increased degrees of activity of the Board of Directors (six) the Nominees,
if
elected, intend to consider, if practicable, establishment of Executive and
Compensation committees in accordance with the new legislation (Sarbanes-
Oxley
Act of 2002) and the procedures set forth in the Company's by-laws.
DIRECTORS'
COMPENSATION
Directors'
compensation is determined by the Board and directors are not compensated
as
such (except through option grants). Presently, the Board has not established
a
compensation committee nor does it have a standard policy regarding compensation
of members of the Board of Directors. In the past, the Board has granted
directors stock options and restricted common stock, in order to assure that
the
directors have an opportunity for and/or have an ownership interest in common
with other stockholders. The Nominees, if elected, may require the Board
or
Compensation Committee, if and when established, among other things, to adopt
a
standard policy regarding compensation of members of the Board.
7
EXECUTIVE
COMPENSATION
The
following table sets forth the compensation paid to the executive officers
of
the registrant for the three years ended December 31, 2005:
|
Summary
Compensation Table
|
||||||||
|
|
Annual
Compensation
|
Long
Term Compensation
|
||||||
|
|
Awards
|
|
Payouts
|
|
||||
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
(i)
|
|
Name
and Principal Position
|
Year
|
Salary($)
|
Bonus($)
|
Other
Annual Compensation-($)*
|
Restricted
Stock Award(s) ($)
|
Securities
Underlying Options/ SARs(#)
|
LTIP
Payouts ($)
|
All
Other Compensation ($)
|
|
|
|
|
|
|
|
|
|
|
|
Andrew
Makrides
President,
CEO,
Chairman
of
the
Board
|
2005
|
$186,418
|
3,428
|
--
|
--
|
25,000
|
--
|
--
|
|
2004
|
$167,320
|
3,189
|
9,921
|
--
|
25,000
|
--
|
--
|
|
|
2003
|
$158,406
|
2,967
|
9,942
|
--
|
110,000
|
--
|
--
|
|
|
|
||||||||
|
J.
Robert
|
2005
|
$256,173
|
4,854
|
--
|
--
|
25,000
|
--
|
--
|
|
Saron
President
of Aaron
Medical
and
Director
|
2004
|
$233,036
|
4,515
|
16,533
|
--
|
25,000
|
--
|
--
|
|
2003
|
$219,786
|
4,200
|
15,568
|
--
|
110,000
|
--
|
--
|
|
|
|
||||||||
|
Moshe
|
2005
|
$193,451
|
3,567
|
--
|
--
|
25,000
|
--
|
--
|
|
Citronowicz
Executive
Vice
President-
Chief
Operating
Officer
|
2004
|
$170,766
|
3,318
|
15,848
|
--
|
25,000
|
--
|
--
|
|
2003
|
$158,637
|
3,086
|
14,345
|
--
|
110,000
|
--
|
--
|
|
|
|
||||||||
|
Charles
|
2005
|
$50,515
|
--
|
---
|
--
|
25,000
|
--
|
--
|
|
Peabody
|
2004
|
$81,825
|
1,579
|
7,893
|
--
|
25,000
|
--
|
--
|
|
Chief
|
2003
|
$77,221
|
1,532
|
6,216
|
--
|
60,000
|
--
|
--
|
|
Financial
|
||||||||
|
Officer
(**)
|
||||||||
(*)
Other
compensation consists of medical insurance and auto.
(**)
Charles Peabody resigned as Vice President, Secretary and Chief Financial
Officer in August 9, 2005
No
options were granted or issued to any executive officer or director during
fiscal year ending December 31, 2002. In 2003 and 2004, a total of 585,000
and
225,000 options were granted to executive officers and directors,
respectively.
8
Option
Grants Table:
The
following table sets forth, with respect to grants of stock options made
during
2005 to each of the Named Executive Officers: (I) the name of the executive
officer (column (a)); (ii) the number of securities underlying options granted
(column (b)); (iii) the percent the grant represents of the total options
granted to all employees during 2005; (iv) the per share exercise price of
the
options granted (column (d)); (v) the expiration date of the options (column
(e)); and (vi) the potential realizable value of each grant, assuming the
market
price of the Common Stock appreciates in value from the date of grant to
the end
of the option term at a rate of (A) 5% per annum (column (f)) and (B) 10%
per
annum (column (g)).
Option
Grants in 2005:
|
|
Individual
Grants
|
Potential
Realizable
Value
at Assumed Annual Rates of Stock Price Appreciation for Option
Term
|
||||
|
Name
(a)
|
Number
of Securities
Underlying
Options Granted
(b)
|
%
of Total Options
Granted
to Employees in 2005
(c)
|
Exercise
or Base Price per Share
(d)(1)
|
Expiration
Date
(e)
|
5%($)
(f)
|
10%($)
(g)
|
|
Charles
Peabody(CFO)(3)
|
25,000
|
5.85%
|
2.25
|
05/05/15
|
||
|
Moshe
Citronowicz(COO)
|
25,000
|
5.85%
|
2.25
|
05/05/15
|
$
35,375
|
$
89,648
|
|
J.
Robert Saron(2)
|
25,000
|
5.85%
|
2.25
|
05/05/15
|
$
35,375
|
$
87,648
|
|
Andrew
Makrides(CEO)
|
25,000
|
5.85%
|
2.25
|
05/05/15
|
$
35,375
|
$
87,648
|
Total
options granted were 427,500 which represent 100% of the options granted
in
2005, all of which are restricted.
|
(1)
|
Such
restricted stock options were granted at an exercise price equal
to 100%
of fair market value on the date of grant.
|
|
(2)
|
President
of Aaron Medical Industries, Inc., our subsidiary.
|
|
(3)
|
Resigned
his position on August 9, 2005.
|
9
Equity
Compensation Plan Information:
|
Plan
category
|
Number
of Securities
to
be issued upon
exercise
of
outstanding
options,
|
Weighted-average
exercise
price of
outstanding
options,
warrants
and rights
|
Number
of securities
remaining
available
for
future issuance
under
equity
compensation
plans
|
|
Equity
compensation Plans approved by Security holders
|
|
|
|
|
|
|
|
|
|
3,751,370
|
$1.14
|
483,300
|
|
|
Total
|
4,168,870
|
1.25
|
483,300
|
The
following table summarizes: (1) The options granted in the last fiscal year
2005; and (2) The aggregated option exercises in the last fiscal year and
the
fiscal year-end option values.
Aggregate
Options/SAR Exercises and Options/SAR Values in the Fiscal Year Ended December
31, 2005 were:
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
||
|
Name
|
Shares
Acquired on Exercise (#)
|
Value
Realized ($)
|
Number
of Securities Underlying Unexercised Options/SARs at December 31,
2005
(#)
|
Value
of Unexercised In-the Money Options/SARs at December 31, 2005($)
(1)
|
||
|
|
|
|
|
|||
|
Exercisable
|
Unexercisable
|
Exercisable
|
Unexercisable
|
|||
|
Andrew
Makrides
|
-
|
-
|
535,000
|
-
|
1,080,800
|
-
|
|
Alfred
Greco (2)
|
-
|
-
|
--
|
-
|
--
|
-
|
|
George
Kromer
|
-
|
-
|
440,000
|
-
|
868,325
|
-
|
|
Moshe
Citronowicz
|
25,000
|
72,000
|
465,000
|
-
|
952,200
|
-
|
|
Rob
Saron
|
-
|
-
|
555,000
|
-
|
1,141,650
|
-
|
|
Brian
Madden
|
-
|
-
|
85,000
|
-
|
66,300
|
-
|
|
Michael
Norman
|
-
|
-
|
60,000
|
-
|
46,800
|
-
|
|
Charles
Peabody (3)
|
-
|
-
|
--
|
-
|
--
|
-
|
|
Randy
Rossi
|
-
|
-
|
--
|
-
|
--
|
-
|
|
|
||||||
|
Total
|
25,000
|
72,500
|
2,190,000
|
-
|
4,195,575
|
-
|
|
(1)
|
Assumes
$2.98 per share fair market value on December 31, 2005 which was
the
closing price on December 31, 2005, the last day of trading on
American
Stock Exchange in 2005.
|
|
(2)
|
Mr.
Greco received 25,000 restricted options in 2005. He resigned his
position
on the board on May 9, 2005 but still remains corporate
counsel.
|
|
(3)
|
Mr.
Peabody resigned his position as CFO on August 9,
2005.
|
10
In
2003,
the Board of Directors adopted and Stockholders approved Bovie’s 2003 Executive
and Employee Stock Option Plan covering a total of one million two hundred
thousand (1,200,000) shares of common stock issuable upon exercise of options
to
be granted under the Plan. In 2004, the Board of Directors granted 25,000
options to each Executive Officer and Directors totaling 225,000 shares.
Outside
Directors are compensated in their capacities as Board members through option
grants. Our Board of Directors presently consists of J. Robert Saron, Andrew
Makrides, Chairman, CEO and President, George W. Kromer, Jr., Randy Rossi,
Michael Norman and Brian Madden. Alfred Greco, who resigned as a director
in
May, 2005, is the managing director of Alfred V. Greco PLLC, a partner of
Sierchio, Greco and Greco, LLP counsel to Bovie, to which Bovie paid legal
fees
of $80,400 during 2005.
There
have been no changes in the pricing of any options previously or currently
awarded.
In
January, 2004, we extended employment contracts with certain of our officers
for
six years. The employment agreements provide, among other things, that the
Executive may be terminated as follows:
|
(a)
|
Upon
the death of the Executive and the Executive’s estate shall be paid the
basic annual compensation due the Employee pro-rated through the
date of
termination.
|
|
(b)
|
By
the Resignation of the Executive at any time upon at least thirty
(30)
days prior written notice to Bovie; and Bovie shall be obligated
to pay
the Employee the basic annual compensation due him pro-rated to
the
effective date of termination,
|
|
(c)
|
By
Bovie, for cause if during the term of the Employment Agreement
the
Employee violates the provisions of Paragraph 12 hereof, or is
found
guilty in a court of law of any crime of moral
turpitude.
|
|
(d)
|
By
Bovie, without cause, with the majority approval of the Board of
Directors, at any time upon at least thirty (30) days prior written
notice
to the Executive: and Bovie shall be obligated to pay the Executive
compensation currently in effect including all bonuses, accrued
or
prorate, and expenses up to the date of termination. Thereafter,
for the
period remaining under the contract, Bovie shall pay the Executive
the
salary then in effect at the time of termination payable weekly.
Employee
shall not have to account for other compensation other sources
or
otherwise mitigate his damages due to such termination.
|
|
(e)
|
If
Bovie terminates the agreement, without cause, or fails to meet
its
obligations to the Executive on a timely basis, or if there is
a change in
the control of Bovie, the Executive may elect to terminate his
employment
agreement. Upon any such termination or breach of any of its obligations
under the Employment Agreement, Bovie shall pay the Executive a
lump sum
severance equal to three times the annual salary and bonus in effect
the
month preceding such termination or breach as well as any other
sums which
may be due under the terms of the Employment Agreement up to the
date of
termination.
|
11
The
following schedule shows all contracts and terms with officers of Bovie.
|
Bovie
Medical Corporation
|
||||
|
December
31, 2005
|
||||
|
|
Contract
|
Expiration
|
Current
|
Auto
|
|
|
Date
|
Date(1)
(2)
|
Base
Pay
|
Allowance
|
|
Andrew
Makrides
|
01/01/98
|
1/31/2009(1)
|
$178,274
|
$
6,067
|
|
J.
Robert Saron
|
01/01/98
|
1/31/2009(1)
|
252,410
|
6,067
|
|
Moshe
Citronowicz
|
01/01/98
|
1/31/2009(1)
|
185,482
|
6,067
|
|
Charles
Peabody*
|
--
|
|||
*
Mr.
Peabody resigned as Secretary and Chief Financial Officer on August 9,
2005.
|
(1)
|
Includes
total extensions for six years- Salaries increase annually pursuant
to a
contract formula. In the event of a change in control, each officer’s
contract contains an option for each respective officer to resign
and
receive 3 years salary.
|
|
(2)
|
If
not cancelled 30 days prior to year-end, the contract automatically
renews
for one year periods.
|
The
following table sets forth certain information as of December 31, 2005, with
respect to the beneficial ownership of the Company’s common stock by all persons
known by the Company to be the beneficial owners of more than 5% of its
outstanding shares, by directors who own common stock and/or options to purchase
common stock and by all officers and directors as a group.
|
|
Number
of Shares
|
|
|
|
|
|
Nature
of
|
Percentage
of
|
||
|
Name
and Address
|
Title
|
Owned
(i)
|
Ownership
|
Ownership(i)
|
|
The
Frost National Bank
|
Common
|
1,000,000
|
Beneficial
|
5.5%
|
|
FBO
Renaissance
|
|
|
|
|
|
US
Growth Investment
|
|
|
|
|
|
Trust
PLC.
|
|
|
|
|
|
Trust
no. W00740100
|
|
|
|
|
|
|
|
|
|
|
|
The
Frost National Bank
|
Common
|
1,000,000
|
Beneficial
|
5.5%
|
|
FBO,
BFS US Special
|
|
|
|
|
|
Opportunities
Trust PLC.
|
|
|
|
|
|
Trust
no. W00118000
|
|
|
|
|
|
Directors
and Officers )
|
Common
|
850,800
|
Beneficial
|
5.8%
|
|
Andrew
Makrides (ii)
|
||||
|
734
Walt Whitman Road
|
||||
|
Melville,
NY 11746
|
||||
|
George
Kromer (iii)
|
Common
|
440,000
|
Beneficial
|
3.0%
|
|
P.O.
Box 188
|
||||
|
Farmingville,
NY 11738
|
||||
12
|
|
|
|
|
|
|
J.
Robert Saron (iv)
7100
30th
Avenue North
St.
Petersburg, FL 33710
|
Common
|
799,363
|
Beneficial
|
5.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Moshe
Citronowicz (v)
7100
30th
Avenue North
St.
Petersburg, FL 33710
|
Common
|
639,591
|
Beneficial
|
4.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brian
Madden (vi)
300
Garden City Plaza
Garden
City, NY 11530
|
Common
|
85,000
|
Beneficial
|
.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mike
Norman (vii)
|
Common
|
60,000
|
Beneficial
|
.4%
|
|
410
Jericho Tpke,
|
|
|
|
|
|
Jericho,
NY
|
|
|
|
|
|
|
|
|
|
|
|
Randy
Rossi (viii)
|
Common
|
60,000
|
Beneficial
|
.4%
|
|
19
Bubbling Brook Rd.,
|
|
|
|
|
|
Walpole,
Mass
|
|
|
|
|
|
|
|
|
|
|
|
Officers
and Directors as a group(7 Persons) (ix)
|
|
2,934,754
|
|
18%
|
|
(i)
|
Based
on 14,040,728 outstanding shares of Common Stock and 4,168,870
outstanding
options to acquire a like number of shares of Common Stock as of
December
31, 2005, of which officers and directors owned a total of 2,190,000
options and 744,753 shares at December 31, 2005. We have calculated
the
percentages on the basis of the amount of outstanding securities
plus, for
each person or group, any securities that person or group has the
right to
acquire within 60 days pursuant to options, warrants, conversion
privileges or other rights.
|
|
(ii)
|
Includes
315,800 shares and 535,000 shares reserved pursuant to ten year
options owned by Mr. Makrides to purchase shares of Common Stock
of the
Company. Exercise prices for his options range from $.50 for 155,000
shares to $3.25 for 25,000 shares.
|
|
(iii)
|
Includes
440,000 shares reserved pursuant to ten year options owned by Mr.
Kromer
to purchase shares of the Company. Exercise prices for his options
range
from $.50 for 100,000 shares to $3.25 for 25,000
shares.
|
|
(iv)
|
Includes
555,000 shares reserved pursuant to 10 year options owned by Mr.
Saron,
exercisable at prices ranging from $.50 per share for 155,000 shares,
and
$3.25 per share for 25,000 shares.
|
|
(V)
|
Includes
465,000 shares reserved pursuant to 10 year options owned by Mr.
Citronowicz exercisable at prices ranging from $.50 for 155,000
shares to
$3.25 for 25,000 shares.
|
|
(vi)
|
Includes
85,000 shares reserved pursuant to 10 year options owned by Mr.
Madden
exercisable at prices ranging from $3.25 for 25,000 to $2.13 for
25,000
options to purchase Common Stock. Mr. Madden has no financial interest
in
25,000 shares of Bovie owned by his
wife.
|
13
|
(vii)
|
Includes
60,000 shares reserved pursuant to 10 year options owned by Mr.
Norman
exercisable at prices ranging from $2.13 for 25,000 shares to $2.25
for
35,000 shares.
|
|
(viii)
|
Includes
50,000 share reserved pursuant to 10 year options owned by Mr.
Rossi
exercisable at price ranging from $2.13 for 25,000 to $2.25 for
25,000
shares.
|
|
(ix)
|
Includes
2,190,000 shares reserved for outstanding options owned by all
Executive
Officers and directors as a group. The last date options can be
exercised
is May 5, 2015.
|
Recent
Developments
In
1998,
Maxxim Medical Corporation (“Maxxim”), a then publicly owned corporation,
acquired 3,000,000 shares of our common stock from us pursuant to a certain
agreement in exchange for assets and equipment, the ownership of the trade
name
“Bovie” and other future business to be conducted between our corporations. As
part of the agreement, Maxxim was granted rights to demand that we register
the
shares with the SEC. Maxxim later became a privately owned corporation. Maxxim
allegedly sold the Bovie common stock to ACMI Corporation (“ACMI”) in 2000.
After a continuing dispute between Maxxim and ACMI, in May, 2004 a bankruptcy
court declared ACMI the owner of the 3,000,000 Bovie shares.
In
September 2004, ACMI Corporation privately sold the 3,000,000 shares to a
limited number of sophisticated accredited investors. As part of the sale,
ACMI
Corporation assigned the demand registration rights to the accredited investors.
Shortly after completion of the sale by ACMI Corporation, the accredited
investors exercised their registration rights and demanded that we file the
registration statement with the SEC covering the 3,000,000 shares of common
stock. We filed the registration statement as requested for the 3,000,000
shares
of common stock and listed the accredited investors as selling stockholders
(the
“Selling Stockholders”). The registration statement became effective in
September, 2005. All proceeds from any sale of shares of our Company pursuant
to
the registration statement are for the benefit of the Selling Stockholders
and
not Bovie. However, pursuant to separate agreement with ACMI and the Selling
Stockholders, we have been reimbursed for our legal, accounting and other
expenses incurred in connection with the offering.
In
2005,
the Executive Officers and directors were awarded a total of 225,000
non-qualified restricted options to purchase our Common Stock at an exercise
price of $2.25 per share expiring on May 5, 2015. (See Executive
Compensation)
Alfred
V.
Greco, a former director, is the principal of Alfred Greco PLLC, a partner
of
Sierchio, Greco and Greco the Company’s counsel. Alfred V. Greco PLLC received
$80,400 and $63,650 in legal fees for the years 2005 and 2004, respectively.
See
“Beneficial Ownership of Securities”. Mr. Greco resigned as a director in May
2005 for personal reasons.
A
director and employee, George Kromer, also served as a consultant to us with
consulting compensation of $22,906 and $20,751 for 2005 and 2004, respectively.
Two
relatives of the chief operating officer of the Company are employed by the
Company. Yechiel Tsitrinovich, an engineering consultant received compensation
for 2005 and 2004 of $79,776 and $79,776 respectively. The other relative,
Arik
Zoran, is an employee of the Company in charge of the engineering department.
He
had a two year contract providing for a salary of $90,000 per year plus living
expenses and benefits which has been extended. For 2005 and 2004 he was paid
$157,045 and $144,314 which includes living expenses and benefits. The Company
is attempting at this time to secure a permanent work visa for Mr. Zoran.
14
The
following table sets forth the aggregate fees billed to us for fiscal years
ended December 31, 2005 and 2004 by Bloom & Co., LLP, our
auditors:
|
|
|
2005
|
|
2004
|
|
||
|
Audit
Fees (1)
|
|
$
|
130,027
|
|
$
|
133,442
|
|
|
|
|
|
|
|
|
|
|
|
Non-Audit
Fees:
|
|
|
|
|
|
|
|
|
Audit
Related Fees(2)
|
|
|
25,000
|
|
|
--
|
|
|
Tax
Fees(3)
|
|
|
5,000
|
|
|
5,000
|
|
|
All
other Fees(4)
|
|
|
--
|
|
|
--
|
|
|
Total
Fees paid to Auditor
|
|
$
|
160,027
|
|
$
|
138,442
|
|
|
(1)
|
Audit
fees consist of fees billed for professional services rendered
for the
audit of Bovie’s annual financial statements and review of the interim
consolidated financial statements included in quarterly reports
and
services that are normally provided by Bloom & Co., LLP in connection
with statutory and regulatory filings or engagements.
|
|
(2)
|
Audit-Related
fees consist of fees billed for assurance and related services
that are
reasonably related to the performance of the audit or review of
Bovie’s
consolidated financial statements and are not reported under “Audit Fees”.
During 2005 our auditor performed services and received fees relating
to
the filing of a Form S-3 with the SEC which constituted Audit Related
Fees.
|
|
(3)
|
Tax
fees consist of fees billed for professional services rendered
for tax
compliance, tax advice and tax planning (domestic and international).
These services include assistance regarding federal, state and
international tax compliance, acquisitions and international tax
planning.
|
|
(4)
|
All
other fees consist of fees for products and services other than
the
services reported above. In the past the Board of Directors had
considered
the role of Bloom & Co., LLP in providing certain tax services to
Bovie and had concluded that such services were compatible with
Bloom
& Co., LLP’s independence as our auditors. In addition, since the
effective date of the SEC rules stating that an auditor is not
independent
of an audit client if the services it provides to the client are
not
appropriately approved (which was previously done by the Board
of
Directors). Now the Audit Committee will pre-approve all audit
and
permissible non-audit services provided by the independent
auditors.
|
Audit
Committee:
The
Audit
Committee has adopted a policy for the pre-approval of services provided
by the
independent auditors, pursuant to which it may pre-approve any service
consistent with applicable law, rules and regulations. Under the policy,
the
Audit Committee may also delegate authority to pre-approve certain specified
audit or permissible non-audit services to one or more of its members, including
the Chairman. A member to whom pre-approval authority has been delegated
must
report its pre-approval decisions, if any, to the Audit Committee at its
next
meeting, and any such pre-approvals must specify clearly in writing the services
and fees approved. Unless the Audit Committee determines otherwise, the term
for
any service pre-approved by a member to whom pre-approval authority has been
delegated is twelve months.
15
Prior
to
September 29, 2003 the audit committee consisted of the board of directors.
On
September 29, 2003 the board of directors appointed Brian Madden, George
Kromer
(both independent directors) and Andrew Makrides as audit committee members.
Mr.
Madden was considered audit committee financial expert until Mr. Michael
Norman
CPA was made a board member on September 23, 2004. The audit committee is
presently made up of three members, George Kromer (Chairman), Michael Norman,
CPA (Financial Expert) and Brian Madden.
OTHER
BUSINESS
Stockholder
Proposals for Inclusion in Proxy Statement
Pursuant
to the Company's policy, stockholders may present proper proposals for inclusion
in the Company's proxy statement and for consideration at the Company's next
annual meeting of stockholders. To be eligible for inclusion in the Company's
2007 Proxy Statement, a stockholder's proposal must be received by the Company
no later than April 11, 2007 and must otherwise comply with Rule 14a-8 under
the
Exchange Act.
Stockholder
Proposals for Annual Meeting
For
business to be properly brought before an annual meeting by a stockholder,
in
addition to any other applicable requirements, timely notice of the matter
must
be first given to Bovie. To be timely, written notice must be received by
Bovie
at its Melville, N.Y. office by the deadline in last year's proxy statement.
If
the proposal is submitted for a regularly scheduled annual meeting, the proposal
must be received at Bovie's principal executive offices not less than 120
calendar days before the date of the Company's proxy statement released to
stockholders in connection with the previous year's annual meeting; or (b)
if
the date of this year's annual meeting has been changed by more than 30 days
from the date of the previous year's meeting, then the deadline is a reasonable
time before the Company begins to print and mail its proxy materials. While
the
Board of Directors will consider stockholder proposals, the Company reserves
the
right to omit from the Company's 2006 Proxy Statement stockholder proposals
that
it is not required to include under federal regulations.
Stockholder
Nominations of Directors
The
Board
of Directors adopted, as part of the director selection process, a policy
for
director selection, which includes consideration of potential director nominees
recommended by stockholders. The Board will identify, evaluate and select
potential director nominees, including nominees recommended by you, using
qualitative standards and certain procedures, as described under the Board
of
Directors, Director Selection above, for recommendation to the Board of
Directors for selection. Any stockholder entitled to vote for the election
of
directors at a meeting may nominate persons for election as directors only
if
timely written notice of such stockholder's intent to make such nomination
is
given, either by personal delivery or United States mail, postage prepaid,
to
Mr. Andrew Makrides, President, Bovie Medical Corporation, 734 Walt Whitman
Road, Suite 207, Melville, NY 11747. Refer to the section entitled the Board
of
Directors, Director Selection beginning on page 4 for more
information.
Costs
of Solicitation
Bovie
is
making this solicitation of proxies and is responsible for the payment of
all
expenses incurred in connection with the solicitation. Management estimates
that
the cost of solicitation of proxies will be approximately $20,000 to be incurred
solely by Bovie.
16
PROPOSAL
ONE
ELECTION
OF DIRECTORS
The
Board
of Directors has nominated all of the current directors for re-election at
the
Annual Meeting. All directors serve until the next Annual Meeting of
stockholders or until their successors are duly elected and
qualified.
THE
NOMINEES
We
have
previously set forth in this Proxy Statement, information - provided by the
nominees - concerning their principal occupation, business experience and
other
matters. See “Management”.
|
THE
BOARD RECOMMENDS THAT YOU VOTE "FOR" EACH OF THE FOLLOWING
NOMINEES.
|
|
ANDREW
MAKRIDES
|
|
J.
ROBERT SARON
|
|
RANDY
ROSSI
|
|
MICHAEL
NORMAN
|
|
GEORGE
W. KROMER, JR.
|
|
BRIAN
H. MADDEN
|
PROPOSAL
TWO
RATIFICATION
OF SELECTION OF AUDITORS
The
Board
of Directors has selected BLOOM & CO., LLP ("BLOOM") as the independent
auditors of Bovie for fiscal year ending December 31, 2006. BLOOM has served
as
the independent auditors of the Company since 1983. Arrangements have been
made
for a representative of BLOOM to attend the Annual Meeting. The representative
will have an opportunity to make a statement if he or she desires to do so,
and
will be available to respond to appropriate stockholder questions. The selection
of BLOOM as the Company's auditors must be ratified by a majority of the
votes
cast at the Annual Meeting. BLOOM is a member of the PCAOB and the Securities
and Exchange Division of the American Institute of Certified Public Accountants
("AICPA") duly authorized to perform audits of SEC registrants. The firm
is
current with its peer review system and has maintained an unqualified quality
control status since the inception of the peer review system established
by the
AICPA.
Audit
Fees. The aggregate fees billed by our auditors for services rendered for
the
audit of our financial statements for the fiscal year ended December 31,
2005
and the review of the Company's financial statements included in our quarterly
filings on Form 10QSB during that fiscal year were $160,027. There were no
other
fees paid for other services performed by Bloom & Co., LLP or its
employees.
THE
BOARD
RECOMMENDS THAT YOU VOTE "FOR" RATIFICATION OF BLOOM & CO., LLP AS THE
COMPANY'S INDEPENDENT AUDITORS FOR 2006.
17
BOVIE
MEDICAL CORPORATION
PROXY
PROXY
FOR
THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON September 14, 2006, THIS
PROXY
IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The
undersigned hereby acknowledges receipt of Notice of Annual Meeting of
Stockholders and Proxy Statement of Bovie Medical Corporation in connection
with
the 2006 Annual Meeting to be held on September 14, 2006, and appoints Andrew
Makrides and George W. Kromer, Jr., or either of them, Proxy with power of
substitution, for and in the name of the undersigned, and hereby authorizes
each
or either of them to represent and to vote, all the shares of common stock
of
Bovie Medical Corporation, a Delaware corporation ("Company"), that the
undersigned would be entitled to vote at the Company's Annual Meeting of
Stockholders ("Annual Meeting") on September 14, 2006 and at any adjournments
thereof, upon the matters set forth in the Notice of Annual Meeting, hereby
revoking any Proxy heretofore given. The Proxies are further authorized to
vote
in their discretion upon such other business as may properly come before
the
Annual Meeting. This proxy will be voted as specified. If no direction is
made,
this proxy will be voted in favor of all proposals.
THE
BOARD
RECOMMENDS A VOTE "FOR" EACH NOMINEE AND FOR PROPOSAL 2.
1.
Election of Directors (check one box only)
|
FOR
[ ] AGAINST [ ]
|
|
|
EACH
NOMINEE LISTED:
|
|
|
Andrew
Makrides
|
|
|
J.
Robert Saron
|
|
|
Randy
Rossi
|
|
|
Michael
Norman
|
|
|
George
W. Kromer, Jr.
|
|
|
Brian
Madden
|
|
|
(Instruction:
To withhold authority to vote for any nominee, circle that nominee's
name
in the above list)
|
|
|
(Continued
and to be signed and dated on reverse side)
|
|
|
(Back
of Proxy)
|
|
|
PROXY
|
|
|
(Please
sign and date below)
|
|
18
|
2.
|
To
ratify the selection of BLOOM & CO., LLP as independent auditors for
the Company.
|
|
FOR
[ ] AGAINST [ ] ABSTAIN [ ]
|
|
|
Dated:_________________________,
2006
|
|
|
----------------------------------------------------
|
|
|
(Please
Print Name)
|
|
|
----------------------------------------------------
|
|
|
(Signature
of Stockholder) (Title, if applicable)
|
|
|
----------------------------------------------------
|
|
|
(Please
Print Name)
|
|
|
----------------------------------------------------
|
|
|
(Signature
of Stockholder) (Title, if
applicable)
|
|
NOTE:
PLEASE SIGN YOUR NAME OR NAMES EXACTLY AS SET FORTH HEREON. FOR JOINTLY OWNED
SHARES, EACH OWNER SHOULD SIGN. IF SIGNING AS ATTORNEY, EXECUTOR, COMMITTEE,
TRUSTEE OR GUARDIAN, PLEASE INDICATE THE CAPACITY IN WHICH YOU ARE ACTING.
PROXIES EXECUTED BY CORPORATIONS SHOULD BE SIGNED BY A DULY AUTHORIZED OFFICER.
PLEASE DATE AND SIGN THIS PROXY AND MAIL IT PROMPTLY IN THE ENCLOSED ENVELOPE.
NO POSTAGE IS REQUIRED IF MAILED IN THE UNITED
STATES.